Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  • STATUS
    Recruiting
  • participants needed
    36
  • sponsor
    Memorial Sloan Kettering Cancer Center
Send
Updated on 16 February 2024
See if I qualify
metastasis
carboplatin
pembrolizumab
pemetrexed
treatment regimen
paclitaxel
dyspnea
stage iv non-small cell lung cancer
carboplatin/paclitaxel
systemic therapy
hemoptysis
small cell lung cancer
cisplatin
carboplatin-pemetrexed
cisplatin/pemetrexed

Summary

This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their cancer. The Quad Shot treatment schedule reduces the number of days needed to deliver the radiation treatments, which may be less disruptive to systemic therapy schedules.

Details
Condition Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Age 18years - 100years
Treatment Cyclical Hypofractionated Palliative Radiation (Quad Shot), EORTC QLQ-C30 questionnaire
Clinical Study IdentifierNCT04384146
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically confirmed non-small cell lung cancer with metastatic disease detected on cross-sectional imaging with a plan for one of the following systemic therapies
Carboplatin/paclitaxel
Carboplatin/paclitaxel/pembrolizumab
Carboplatin/pemetrexed
Carboplatin/pemetrexed/pembrolizumab
Pembrolizumab
Cisplatin/pemetrexed
Cisplatin/pemetrexed/pembrolizumab
Patients eligible for the systemic therapy regimens notes
Patients with Stage IV NSCLC who have symptomatic (defined by patient-reported cough, dyspnea, or hemoptysis) or near-symptomatic (determined radiographically to be threatening the airway, esophagus or vasculature) centrally located
KPS 60
Age 18 years
Able to provide informed consent
Patients at reproductive potential must agree to practice an effective contraceptive method

Exclusion Criteria

Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances
Serious medical co-morbidities precluding radiotherapy
Pregnant or breast-feeding women
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

metastasis
carboplatin
pembrolizumab
pemetrexed
treatment regimen
paclitaxel
dyspnea
stage iv non-small cell lung cancer
carboplatin/paclitaxel
systemic therapy
hemoptysis
small cell lung cancer
cisplatin
carboplatin-pemetrexed
cisplatin/pemetrexed

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.